Immunovant Files 2024 10-K

Ticker: IMVT · Form: 10-K · Filed: May 29, 2024 · CIK: 1764013

Sentiment: neutral

Topics: 10-K, biotech, financials

TL;DR

IMVT filed its 2024 10-K, check financials and biz strategy.

AI Summary

Immunovant, Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its operations and financial condition. The company, formerly Health Sciences Acquisitions Corp., is focused on biological products. Its principal executive offices are located at 320 West 37th Street, New York, NY 10018.

Why It Matters

This filing provides a comprehensive overview of Immunovant's financial health and business strategy for the past fiscal year, which is crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a biotechnology company, Immunovant faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Players & Entities

FAQ

What is Immunovant's primary business focus?

Immunovant, Inc. is focused on Biological Products (No Diagnostic Substances) as indicated by its SIC code [2836].

When did the company change its name from Health Sciences Acquisitions Corp.?

The company's name change from Health Sciences Acquisitions Corp. occurred on 20190108.

What is the SEC file number for Immunovant?

The SEC file number for Immunovant, Inc. is 001-38906.

What is the state of incorporation for Immunovant?

Immunovant, Inc. is incorporated in Delaware (DE).

What is the fiscal year end date for Immunovant?

Immunovant's fiscal year ends on March 31 (0331).

Filing Stats: 4,401 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2024-05-29 16:36:00

Key Financial Figures

Filing Documents

RISK FACTORS

ITEM 1A. RISK FACTORS 46

UNRESOLVED STAFF COMMENTS

ITEM 1B. UNRESOLVED STAFF COMMENTS 99

CYBERSECURITY

ITEM 1C. CYBERSECURITY 99

PROPERTIES

ITEM 2. PROPERTIES 101

LEGAL PROCEEDINGS

ITEM 3. LEGAL PROCEEDINGS 101

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 101 PART II

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 102

[RESERVED]

ITEM 6. [RESERVED] 102

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 103

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 113

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 114

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 137

CONTROLS AND PROCEDURES

ITEM 9A. CONTROLS AND PROCEDURES 137

OTHER INFORMATION

ITEM 9B. OTHER INFORMATION 139

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 139 PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 140

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 140

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 140

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 140

PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 140 PART IV

EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES 141

FORM 10-K SUMMARY

ITEM 16. FORM 10-K SUMMARY 143

SIGNATURES

SIGNATURES 144 All trademarks, trade names, service marks, and copyrights appearing in this Annual Report on Form 10-K are the property of their respective owners. Table of Content s CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K for the fiscal year ended March 31, 2024 (this "Annual Report") contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words "anticipate," "believe," "can," "continue," "could," "design," "estimate," "expect," "forecast," "goal," "hope," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will" and "would," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: the timing, progress, costs and results of our clinical trials for our product candidates, IMVT-1402 and batoclimab, formerly referred to as IMVT-1401; potential therapeutic benefits and risks in current and future indications and the ability to achieve regulatory approval in licensed jurisdictions; future operating or financial results and cash position; future acquisitions, business strategy and expected capital spending; the timing of meetings with and feedback from regulatory authorities as well as an

Business

Item 1. Business Overview We are a clinical-stage immunology company pursuing a broad anti-FcRn strategy based on the potential best-in-class profile of our lead asset, IMVT-1402, and informed by the breadth of the class, in which 23 indications have been publicly announced for study by multiple companies to date. We expect to initiate programs evaluating IMVT-1402 in several therapeutic areas, including endocrinology and neurology. To address the unmet needs of people with autoantibody-driven diseases, we are committed to initiating a broad set of late-stage programs for IMVT-1402, including first-in-class indications such as Graves' disease ("GD"), classic autoantibody indications such as myasthenia gravis ("MG"), and other indications with positive in-class data such as chronic inflammatory demyelinating polyneuropathy ("CIDP"). We expect to leverage disease state insights, clinical trial data observed to date within the anti-FcRn class, and operational experience from past and ongoing batoclimab studies and trials to inform and accelerate the development of IMVT-1402. Our innovative product pipeline includes IMVT-1402 and batoclimab, formerly referred to as IMVT-1401, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor ("FcRn"). Our product candidates are the result of a multi-step, multi-year research program conducted in collaboration with HanAll Biopharma Co., Ltd., ("HanAll") to design highly potent anti-FcRn antibodies that may be optimized as a simple, subcutaneous injection with dosing that we believe can be tailored based on disease severity and stage. The physiologic function of FcRn is to prevent the degradation of immunoglobulin G ("IgG") antibodies. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases. Inhibition of FcRn, such as through the use of an anti-FcRn antibody, has been shown to reduce levels of total IgG and pathogenic IgG antibodies. We bel

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing